Portal de Periódicos da CAPES

Results of Micro Biopsy (Tru-Cut) of Breast Cancer in Guinea

2023; Science Publishing Group; Linguagem: Inglês

10.11648/j.ijcocr.20230803.15

2578-9511

Bah Malick, Touré Alhassane Isamael, Keita Mamady, Conde Ibrahima Kalil, Souare Mamadou Bobo, Sy Savané Mariame, Cisse Kalil, Cissé Mohamed Falilou, Traoré Bangaly,

Cancer Genomics and Diagnostics

Objective : The aim was to determine the contribution of Micro-biopsy to the diagnosis of patients with breast cancer. Material and methods : This was a 2-year retrospective observational study from January 1, 2019, to December 31, 2020. It concerned patients with breast pathologies who underwent Micro-biopsy. Results : We enrolled 360 patients with breast pathologies, 47 of whom underwent Micro-biopsy. The mean age of the patients was 43.0 years, with a predominance of females in 45 (95.7%) cases. The primary tumor was classified as T4 in 24 (51.2%) cases. Micro-biopsy yielded an average of 4 cores (4 and 10). Immunohistochemistry was performed abroad (cerba laboratory) in 40 (85.1%) patients. Hormone receptors were positive in 09 patients, including 6 (2.6%) with positive estrogen receptors and 3 (1.3%) with positive progesterone receptors. Her2-positive breast cancers accounted for 3 (1.3%) cases. The Ki67 proliferation index was ≥ 15% in 24 (40.4%) cases. According to the nature of the fine-needle biopsy specimen result, we notified 39 (83.0%) cases of cancer and 7 (15.0%) cases of benign tumor. Conclusion : This preliminary study enabled us to assess the contribution and reliability of Micro-biopsy in the diagnostic arsenal of breast cancer. Micro-biopsy should be performed for all breast nodules. Screening and awareness campaigns will make a considerable contribution to reducing the delay in diagnosis and the morbidity and mortality associated with breast cancer.